Fund That Surged on Rocket Looks to Next Rare Disease Windfall
- Investor gains $500 million in a day on Rocket Pharmaceuticals
- RTW Investments sees more opportunity in gene therapies
This article is for subscribers only.
RTW Investments LP has cemented its place as one of the top performing health-care hedge funds after an almost $500 million gain from its largest investment, Rocket Pharmaceuticals Inc.
Rocket -- which develops treatments for rare diseases in children -- surged 83% in a single day last week on positive results from an experimental gene therapy for a heart muscle disorder.